Compare

Tecan Group AG/Fr. TECN

1D1W1M3M6MYTD1Y5YMAX

About Tecan Group AG

Tecan Group AG is a Switzerland-based company operating in the life sciences industry, primarily providing laboratory instruments and solutions for automated workflows. Founded in 1980 and headquartered in Männedorf, Switzerland, the company designs and manufactures a range of products including liquid handling and robotic workflow solutions, microplate readers, and various laboratory software applications. Tecan's products serve laboratories in biopharmaceuticals, forensics, and diagnostics sectors, enhancing productivity and precision in research processes. Leveraging its technological expertise, Tecan emphasizes modular and scalable solutions that cater to diverse laboratory needs globally. Its strategic positioning revolves around innovation in automation technology to improve laboratory efficiency.
Ticker
Fr. TECN
Sector
Health
Primary listing
XSWX
Employees
3,000
Headquarters
Männedorf, Switzerland
Website
www.tecan.com

Tecan Group AG Metrics

BasicAdvanced
CHF 3B
-
-CHF 9.30
1.01
CHF 3.00
0.61%

What the Analysts think about Tecan Group AG

Analyst ratings (Buy, Hold, Sell) for Tecan Group AG stock.
Analyst projections of the future price of Tecan Group AG stock.

Bulls say / Bears say

First-half sales grew 3.4% in local currencies and orders rose 3.0%, with book-to-bill above one in both segments. That points to demand running ahead of sales and growth in both parts of the business. (Tecan Group AG)
Underlying profitability improved by 180 basis points despite currency and tariff headwinds, and Tecan expects its full-year adjusted EBITDA margin to reach the upper end of its 15.5%–16.5% range. Early benefits from its Rewired programme could support further efficiency gains. (Tecan Group AG)
Tecan is building new routes to growth through AI-enabled lab analytics and a direct sales and service presence in India. These initiatives may expand its reach, although the AI opportunity is still at an early stage. (Tecan, Tecan)
The recovery remains patchy: academic and government sales fell by double digits, and management said customers remain cautious as funding has yet to flow through to orders. That limits confidence in a broad-based rebound. (MarketScreener)
Cash generation and reported earnings were weak in the first half: operating cash flow fell 71.7% and net profit fell 31.5%. Gross margin also declined to 33.9% from 36.2%, suggesting the recovery has not yet translated into stronger underlying economics. (VermögensZentrum, Simply Wall St)
Currency and tariffs remain a drag, while restructuring and major IT upgrades add costs. These pressures could make it harder to deliver the targeted margin gains, even if local-currency sales continue to grow. (Tecan Group AG)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2026.

Tecan Group AG Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Tecan Group AG Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing Tecan Group AG

AllUSDEURGBP
Funds
Fund name
Fund size
Fr. TECN weighting
iShares Healthcare Innovation£DRDR
$1.3B0.38%
iShares Healthcare Innovation€2B78
$1.2B0.38%
iShares Healthcare Innovation$HEAL
$1.3B0.38%
Xtrackers MSCI Europe Small Cap£XXSC
$3.6B0.24%
Xtrackers MSCI Europe Small Cap€DX2J
$3.6B0.24%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.